Current Developments of Targeting the P53 Signaling Pathway for Cancer Treatment

Overview

Journal Pharmacol Ther

Specialty Pharmacology

Date 2020 Nov 1

PMID 33130194

Citations 62

Authors

Jing Huang

Affiliations

Soon will be listed here.

Abstract

p53 is one of the most well-studied tumor suppressors. It is mutated or deleted in half of all cancers. In the other half carrying wild type p53, the p53 signaling pathway is disrupted by abnormalities of other components in the pathway. Due to its paramount role in tumor suppression, p53 has attracted great interest in drug development as any clinically successful therapeutic agent to target the p53 pathway will save millions of lives. However, designing therapeutics targeting the pathway has been extremely challenging, despite more than forty years of research. This review will summarize past and current efforts of developing p53-based gene therapy and targeted therapies for cancer treatment. In addition, the current efforts of exploiting the immunogenicity of p53 protein for cancer immunotherapy will be reviewed. Challenges and future directions for targeting the p53 pathway will be discussed.

Citing Articles

Integrated bulk and single-cell RNA sequencing to identify potential biomarkers in intervertebral disc degeneration.

Fan C, Xu W, Li X, Wang J, He W, Shen M Eur J Med Res. 2025; 30(1):102.

PMID: 39953636 PMC: 11827443. DOI: 10.1186/s40001-025-02346-4.

Cysteine‑ and glycine‑rich protein 2: A vital regulator that inhibits necroptosis glioma cell by activating the JAK‑STAT1 pathways.

Lv D, Han X, Hao L, Sun Z, Zhang A, Liu J Oncol Rep. 2025; 53(3).

PMID: 39918019 PMC: 11826106. DOI: 10.3892/or.2025.8873.

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis.

Khanna V, Eslami G, Reyes R, Diep R, Fernandez-Pol S, Stehr H NPJ Precis Oncol. 2025; 9(1):34.

PMID: 39900989 PMC: 11790943. DOI: 10.1038/s41698-025-00823-x.

Plant protein-derived anti-breast cancer peptides: sources, therapeutic approaches, mechanisms, and nanoparticle design.

Zhang D, Yuan Y, Zeng Q, Xiong J, Gan Y, Jiang K Front Pharmacol. 2025; 15:1468977.

PMID: 39898323 PMC: 11783187. DOI: 10.3389/fphar.2024.1468977.

Anti-tumor and anti-metastatic effects of RRx-001 on hepatocellular carcinoma: mechanisms of action and therapeutic potential.

Yan G, Zhao S, Chen M, Mo S, Huang H, Liao Y Front Pharmacol. 2024; 15:1469825.

PMID: 39664519 PMC: 11631591. DOI: 10.3389/fphar.2024.1469825.

References

Bykov V, Eriksson S, Bianchi J, Wiman K . Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2017; 18(2):89-102. DOI: 10.1038/nrc.2017.109. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Amelio I, Melino G . Context is everything: extrinsic signalling and gain-of-function p53 mutants. Cell Death Discov. 2020; 6:16. PMC: 7090043. DOI: 10.1038/s41420-020-0251-x. View

Malkin D, Li F, Strong L, Fraumeni Jr J, Nelson C, Kim D . Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250(4985):1233-8. DOI: 10.1126/science.1978757. View

Andreeff M, Kelly K, Yee K, Assouline S, Strair R, Popplewell L . Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2015; 22(4):868-76. PMC: 4809642. DOI: 10.1158/1078-0432.CCR-15-0481. View

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

Hill R, Song Y, Cardiff R, Van Dyke T . Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 2005; 123(6):1001-11. DOI: 10.1016/j.cell.2005.09.030. View

Chang Y, Graves B, Guerlavais V, Tovar C, Packman K, To K . Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013; 110(36):E3445-54. PMC: 3767549. DOI: 10.1073/pnas.1303002110. View

10.

Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

11.

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

12.

Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A . Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988; 8(2):531-9. PMC: 363177. DOI: 10.1128/mcb.8.2.531-539.1988. View

13.

Lambert J, Moshfegh A, Hainaut P, Wiman K, Bykov V . Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2009; 29(9):1329-38. DOI: 10.1038/onc.2009.425. View

14.

Liu Y, Tavana O, Gu W . p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019; 11(7):564-577. PMC: 6736412. DOI: 10.1093/jmcb/mjz060. View

15.

Eliyahu D, Raz A, Gruss P, Givol D, Oren M . Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 1984; 312(5995):646-9. DOI: 10.1038/312646a0. View

16.

Hall A, Dix B, OCarroll S, Braithwaite A . p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med. 1998; 4(9):1068-72. DOI: 10.1038/2057. View

17.

Wang X, Simon R . Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics. 2013; 6:30. PMC: 3847148. DOI: 10.1186/1755-8794-6-30. View

18.

Melero J, Stitt D, Mangel W, Carroll R . Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. Virology. 1979; 93(2):466-80. DOI: 10.1016/0042-6822(79)90250-2. View

19.

Ray-Coquard I, Blay J, Italiano A, Cesne A, Penel N, Zhi J . Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012; 13(11):1133-40. DOI: 10.1016/S1470-2045(12)70474-6. View

20.

Yu X, Vazquez A, Levine A, Carpizo D . Allele-specific p53 mutant reactivation. Cancer Cell. 2012; 21(5):614-625. PMC: 3366694. DOI: 10.1016/j.ccr.2012.03.042. View